about
Factors determining patient-prosthesis mismatch after aortic valve replacement--a prospective cohort studyOutcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular PerformancePrognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis.Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fractionLong-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial Infarction: The 5-Year MYSTAR StudyMyocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers.Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature.Fluid status and outcome in patients with heart failure and preserved ejection fraction.Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome.Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.Modes of death in patients with heart failure and preserved ejection fraction.T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication.Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size.Combined oral administration of L-arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension.Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for CardiovascularModerate patient-prosthesis mismatch after valve replacement for severe aortic stenosis has no impact on short-term and long-term mortality.Size matters! Impact of age, sex, height, and weight on the normal heart size.Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis.Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling : Ready for prime time?Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction.Preserved right ventricular integrity in a new telemetric rat model of severe pulmonary hypertension.Gender-related differences in heart failure with preserved ejection fraction.Dobutamine Stress Echocardiography for Management of Low-Flow, Low-Gradient Aortic Stenosis.Tricuspid valve replacement: results of an orphan procedure: which is the best prosthesis?Right ventricular dysfunction, but not tricuspid regurgitation, is associated with outcome late after left heart valve procedure.Predictors of outcome of non-ischemic mitral valve surgery.Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology.Value and limitations of aortic valve resistance with particular consideration of low flow-low gradient aortic stenosis: an in vitro study.Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction.Facts and alternative facts - basic principles of scientific work.Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection FractionSystemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot studyPrognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitationThe forgotten valve: lessons to be learned in tricuspid regurgitation
P50
Q35061409-F036372B-98FE-49AB-AD9B-63D5A9249481Q35725839-9C763DB4-6B19-41EC-AB93-F24DE96B2881Q35751037-208261D7-11EE-4365-9BAE-84A65EF1F9A3Q36006309-2333F580-D052-4AD4-AA2F-67BF24B8DEADQ36169198-0B594FA8-27B2-4FF8-8C4B-0D30B2B1A0E2Q37278457-0720EF6E-3EF1-46A3-B217-053811B8679EQ37510689-70178BBC-81D3-4CEF-AC04-51B8165997EAQ38095581-E469E699-D7F8-40E8-9C2F-0CA26285A9BBQ39035268-9D91CFAF-7D6B-49AE-95D9-A73924A69AECQ40149965-D1DAD3E9-8D6D-4F61-BF68-5C94F0F7F342Q40179170-8191E88A-1B5A-40C6-AB91-591E6930FBAAQ40425042-B9AC123A-6AD9-4332-B0B6-156F8883BCE7Q40442223-BE7DC03D-D9AA-4E06-A52A-4027F9AAA163Q41036082-DBC6679F-15BF-4C9E-94E6-B1F97760AB75Q41577379-C1C3BE64-DA7C-4FF4-AC00-E3B4A173323FQ42238880-937120D3-DE80-486A-9A10-F41AE8406BE7Q42373017-379EF614-5526-4576-8587-FD170C6CD772Q43488732-CBB701B4-BC70-4847-913C-529BD5CCF00AQ47212185-631E6F21-F3D9-46E1-9A86-4DFDFF4AFF7FQ47397983-8FFFFE8F-4979-4B4E-81FD-5B3DAF50A894Q47567410-BA323BC3-9D28-4BBF-8BFB-8B17F6FBF3DAQ47619369-DA30CEBC-5EDD-48D6-BEA5-8E512F6B7A2FQ47705289-25FD2782-442B-46D6-ABCE-5374EBBE7B9FQ47794661-5FE73695-4CC8-4E6E-97F6-A3D2819F1F86Q47808071-4B39B591-EE31-4733-8112-CDB0F1CFB815Q49342004-EE02AADD-5A16-4744-B034-B58B334F8405Q50059620-D9A2CB4B-B7B1-437A-B6FC-F03932CC3F13Q50070637-07952464-F90D-4026-8DEA-AF59261D5008Q51068239-7E499833-3ECD-44C4-9120-46057DC44FFEQ51422921-3205506A-84A3-482F-B5C4-BB6FFE6793CFQ51663167-6DA3E5E9-95E6-48A6-9C6F-1F1BA034E1C9Q51998364-9E04A347-0CF0-45C9-BF85-553FED450659Q52819862-3B45FF56-5760-40AC-B094-4D7FFCC5FBCFQ53478092-7882DA7C-255B-44F0-BE75-50E346C9AFEFQ54500543-9EE53277-5BAB-40CC-A1BB-B0AC119C0D2FQ55494001-9F5569FD-0914-488B-9922-662D5F5069D6Q58070990-4721D4B8-B841-4267-89A6-09A5690D15CFQ58071123-6A011C5D-8F1E-43DD-AD0E-391237CCA64EQ58071174-1AF0AC26-4169-4BCE-AF95-7F6012912FD2Q58071202-57A1E65B-49B9-403D-9B8D-033AF1EE9868
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Julia Mascherbauer
@ast
Julia Mascherbauer
@en
Julia Mascherbauer
@es
Julia Mascherbauer
@nl
type
label
Julia Mascherbauer
@ast
Julia Mascherbauer
@en
Julia Mascherbauer
@es
Julia Mascherbauer
@nl
prefLabel
Julia Mascherbauer
@ast
Julia Mascherbauer
@en
Julia Mascherbauer
@es
Julia Mascherbauer
@nl
P1153
6507613914
7801484712
P21
P31
P496
0000-0001-7478-1450